TOP TEN perturbations for Q96G42 (Homo sapiens)

Organism: Homo sapiens
Gene: Q96G42
Selected probe(set): 236285_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of Q96G42 (236285_at) across 5610 perturbations tested by GENEVESTIGATOR:

collecting duct carcinoma study 1 / normal kidney tissue

Relative Expression (log2-ratio):5.3078823
Number of Samples:2 / 2
Experimental collecting duct carcinoma study 1
Tumor tissue samples from the kidney of patients with collecting duct carcinoma (CDC).
Control normal kidney tissue
Normal fetal kidney tissue samples.

collecting duct carcinoma study 1 / normal kidney tissue

Relative Expression (log2-ratio):4.658124
Number of Samples:2 / 3
Experimental collecting duct carcinoma study 1
Tumor tissue samples from the kidney of patients with collecting duct carcinoma (CDC).
Control normal kidney tissue
Normal adult kidney tissue samples.

cysteine deprivation study 1 (long) / non-deprivated C3A/HepG2 cell sample

Relative Expression (log2-ratio):4.609825
Number of Samples:3 / 3
Experimental cysteine deprivation study 1 (long)
C3A/HepG2 cells were cultured in sulfur amino acid-free DMEM supplemented only with 0.1 mM methionine (cysteine-free medium) for 42h.
Control non-deprivated C3A/HepG2 cell sample
C3A/HepG2 cells were cultured in sulfur amino acid-free DMEM supplemented with 0.1 mM methionine + 0.1 mM cysteine (complete medium) for 42h.

Rosacea study 1 (PPR) / normal skin tissue

Relative Expression (log2-ratio):4.11919
Number of Samples:12 / 20
Experimental Rosacea study 1 (PPR)
Skin biopsy samples from patients with papulopustular rosacea (PPR), diagnosed in accordance with classification system of the American Rosacea Society. Skin biopsies were taken from nasolabial fold.
Control normal skin tissue
Normal skin biopsy samples from healthy individuals.

vulvar intraepithelial neoplasia study 1 / normal vulva tissue

Relative Expression (log2-ratio):3.8163166
Number of Samples:9 / 10
Experimental vulvar intraepithelial neoplasia study 1
Vulva biopsy of vulvar intraepithelial neoplasia (VIN).
Control normal vulva tissue
Vulva biopsy of normal tissue.

psoriasis study 24 (lesional; baseline; ustekinumab; 90mg; non-responder) / psoriasis study 24 (non-lesional; baseline; ustekinumab; 90mg; non-responder)

Relative Expression (log2-ratio):3.7312336
Number of Samples:10 / 9
Experimental psoriasis study 24 (lesional; baseline; ustekinumab; 90mg; non-responder)
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with 90 mg ustekinumab) and assigned as non-responders. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT.
Control psoriasis study 24 (non-lesional; baseline; ustekinumab; 90mg; non-responder)
Non-lesional and macroscopic normal skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with 90 mg ustekinumab) and assigned as non-responders. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Patients participated in a phase 3 of Psoriasis Trial ACCEPT.

psoriasis study 25 (lesional; baseline; ustekinumab; non-responder) / psoriasis study 25 (non-lesional; baseline; ustekinumab; non-responder)

Relative Expression (log2-ratio):3.7253265
Number of Samples:10 / 9
Experimental psoriasis study 25 (lesional; baseline; ustekinumab; non-responder)
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with ustekinumab) and assigned as non-responders. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT.
Control psoriasis study 25 (non-lesional; baseline; ustekinumab; non-responder)
Non-lesional and macroscopic normal skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with ustekinumab) and assigned as non-responders. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Patients participated in a phase 3 of Psoriasis Trial ACCEPT.

bladder cancer study 3 / normal bladder tissue

Relative Expression (log2-ratio):3.6454124
Number of Samples:3 / 3
Experimental bladder cancer study 3
High grade muscle invasive tumors.
Control normal bladder tissue
Normal bladder tissue.

IL-1b; IFN-g study 1 (132hrs) / untreated pancreatic islet sample (132hrs)

Relative Expression (log2-ratio):3.5387058
Number of Samples:2 / 2
Experimental IL-1b; IFN-g study 1 (132hrs)
Pancreatic islets isolated by collagenase digestion from brain-dead organ donors and cultured 3-5 days in RPMI 1640 medium containing 5.6 mM glucose, 10% FCS and 2 mM L-glutamine. Thereafter, islets were cultured in presence of human recombinant IL-1b (25 units/ml) and IFN-g (1,000 units/ml) for 132 hours. Media were changed after 2 and 5 days.
Control untreated pancreatic islet sample (132hrs)
Untreated pancreatic islets isolated by collagenase digestion from brain-dead organ donors and cultured 3-5 days in RPMI 1640 medium containing 5.6 mM glucose, 10% FCS and 2 mM L-glutamine. Thereafter, islets were cultured in fresh media and harvested after 132 hours. Media were changed after 2 and 5 days.

IL-1b; IFN-g study 1 (108hrs) / untreated pancreatic islet sample (108hrs)

Relative Expression (log2-ratio):3.4850788
Number of Samples:2 / 2
Experimental IL-1b; IFN-g study 1 (108hrs)
Pancreatic islets isolated by collagenase digestion from brain-dead organ donors and cultured 3-5 days in RPMI 1640 medium containing 5.6 mM glucose, 10% FCS and 2 mM L-glutamine. Thereafter, islets were cultured in presence of human recombinant IL-1b (25 units/ml) and IFN-g (1,000 units/ml) for 108 hours. Media were changed after 2 and 5 days.
Control untreated pancreatic islet sample (108hrs)
Untreated pancreatic islets isolated by collagenase digestion from brain-dead organ donors and cultured 3-5 days in RPMI 1640 medium containing 5.6 mM glucose, 10% FCS and 2 mM L-glutamine. Thereafter, islets were cultured in fresh media and harvested after 108 hours. Media were changed after 2 and 5 days.